BMC Cancer

Table 1 Association between mast cell infiltration and patient characteristics

From: Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

			Discovery set (n = 115)					Validation set (n = 135)
Characteristic	Patients		Mast cell infiltration			Patients		Mast cell infiltration
Characteristic	Number	%	Low (n = 50)	High (n = 65)	P ^a	Number	%	Low (n = 70)	High (n = 65)	P ^a
Age, years					0.71					0.61
Mean ± SD^b	62.56 ± 10.26		62.16 ± 11.51	62.86 ± 9.26		63.67 ± 11.62		61.56 ± 11.72	66.18 ± 10.94	0.61
Gender					0.69					0.30
Female	62	53.91	28	34		91	67.41	50	41
Male	53	46.09	22	31		44	32.59	20	24
Tumor location					0.31					0.26
Perihilar	40	10.43	19	21		24	17.78	14	10
Distal	12	63	7	5		10	7.41	3	7
Gallbladder	63	54.78	24	39		101	74.81	57	44
T-stage					0.25					0.91
T1–2	41	35.65	17	24		16	11.85	9	7
T3	44	38.26	16	28		79	58.52	41	38
T4	30	26.09	17	13		40	29.63	20	20
N-stage					0.008					0.87
N0	62	53.91	20	42		114	84.44	59	55
N1,2	53	46.09	30	23		21	15.56	11	10
TNM stage					0.12					0.93
I-II	39	33.91	16	23		16	11.85	9	7
III	36	31.30	11	27		74	54.81	38	36
IV	40	34.79	23	17		45	33.34	23	22
Differentiation					0.98					0.21
Well, Moderate	76	66.09	33	43		59	43.70	27	32
Poor	39	33.91	17	22		76	56.30	43	33
Residual tumor					0.16					0.21
R0	100	86.96	41	59		119	88.15	65	57
R1	15	13.04	9	6		16	11.85	5	9
Vascular invasion					0.49					0.035
Absent	64	55.65	24	27		106	78.52	60	46
Present	51	44.35	26	38		29	21.48	10	19
ACT					0.78					0.49
Absent	65	56.52	29	36		85	62.96	46	39
Present	50	43.48	21	29		50	37.04	24	26

SD standard deviation; ACT = adjuvant chemotherapy
^a, P < 0.05 is considered statistically significant
^b, The results of continuous variables are presented as mean ± SD (standard deviation)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com